Mr. Pratap Sandhu reports

THE PRECISION PEPTIDE COMPANY ACTIVATES NATIONWIDE DIRECT-TO-CONSUMER PEPTIDE SALES WITH RETAIL TELEHEALTH WEBSITE LAUNCH

The Precision Peptide Company Inc. has launched its direct-to-consumer retail and telehealth website across all 50 U.S. states.

Highlights:

• The Precision Peptide Company's newly launched direct-to-consumer and telehealth platform is now available in all 50 states of the United States;
• One-hundred-per-cent-U.S.-compounded peptide products are supported through a 503A compounding agreement.
• July 23, 2026, is the scheduled FDA (U.S. Food and Drug Administration) advisory committee review date for several peptide substances, including BPC-157. The Precision Peptide Company's compounding, telehealth, compliance and consumer sales infrastructure is currently in place. The website brings together oral supplements, transdermal patches, topical products and telehealth services through one consumer-facing platform.
• The transdermal patches provide a differentiated, needle-free format that requires no mixing or cold storage.
• LegitScript health care merchant certification supports compliance, consumer safety, payment processing and advertising standards.
• The launch is extended to expand retail reach and brand visibility as the business advances its commercial rollout.

The website is now live.

The new platform establishes a nationwide sales channel for an expanding portfolio of oral supplements, transdermal patches and topical wellness products. It brings product information, on-line purchasing and telehealth services together through one consumer-facing website.

Consumers can explore and purchase the available product range directly on-line. The website is designed to simplify access to peptide-powered wellness through clear product information, consumer-friendly formats and a streamlined purchasing experience.

The current oral supplement portfolio supports wellness categories including daily energy and vitality, focus and mental energy, muscle, joint and gut support, relaxation and sleep, and gut balance and recovery. Topical products are designed to support scalp, follicle and skin health while the transdermal patch portfolio targets recovery, immunity and other wellness applications. Together, these products give The Precision Peptide Company multiple consumer-ready formats across a range of wellness categories.

Differentiated transdermal patch format

The transdermal patches provide a needle-free format designed for convenient application without mixing or complex administration. Applied directly to the skin, the transdermal patches are intended to fit easily into wellness routines and make peptide-powered wellness more accessible to a broader consumer audience.

The broader transdermal delivery architecture is being developed around stabilization, permeation and sustained-release applications. This strategy is focused on stable, consumer-ready formats that do not require needles, mixing or cold storage.

U.S. compounding, telehealth and compliance infrastructure

The launch builds on the telehealth infrastructure (see news release dated June 9, 2026), together with the 503A compounding agreement (see news release dated June 2, 2026).

Under the agreement, compounded peptide products are to be 100 per cent compounded in the United States.

The platform is also supported by the previously announced LegitScript health care merchant certification. The certification independently supports compliance and consumer safety standards while positioning The Precision Peptide Company to process payments and conduct marketing activities across major payment and advertising platforms.

The platform is designed to align with applicable U.S. legal, HIPAA (Health Insurance Portability and Accountability Act), telehealth and pharmacy regulations and is intended to support secure consumer interactions and continued nationwide expansion.

Direct consumer relationship and commercial opportunity

The launch is intended to establish a direct relationship with consumers and provide the company with additional control over product education, brand presentation and the overall customer experience.

The platform is designed to support customer acquisition, repeat purchasing, future subscription offerings and the introduction of additional products, bringing product education, on-line purchasing and telehealth services together in one place. The website is also intended to expand retail reach and brand visibility as The Precision Peptide Company moves into the next phase of its commercial rollout.

Pratap Sandhu, chief executive officer of The Precision Peptide Company, commented: "This launch brings our product portfolio and the infrastructure we have built together for the customer. Consumers across all 50 states can now explore our oral supplements, topical products and differentiated transdermal patches through one platform.

"This gives us a direct channel with customers, makes peptide-powered wellness more accessible and creates a platform from which we can continue expanding our portfolio across the United States."

Timing ahead of FDA advisory committee review

As previously disclosed, the U.S. Food and Drug Administration has referred several peptides, including BPC-157, to the pharmacy compounding advisory committee, which is scheduled to review these substances at a public meeting on July 23, 2026.

With its U.S.-based 503A compounding agreement, telehealth infrastructure, LegitScript health care merchant certification and consumer-facing retail website now in place, The Precision Peptide Company enters the scheduled review with its U.S. compounding, compliance and consumer sales infrastructure already established and operational.

The platform positions The Precision Peptide Company to respond to future regulatory developments while continuing to expand its product portfolio, consumer reach and commercial presence across the United States.

About The Precision Peptide Company Inc.

The Precision Peptide Company is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.

We seek Safe Harbor.